Anna Marina Liberati
Overview
Explore the profile of Anna Marina Liberati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
2987
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pulsoni A, Ferrero S, Tosti M, Luminari S, Dondi A, Cavallo F, et al.
Lancet Haematol
. 2024 Jun;
11(7):e499-e509.
PMID: 38937025
Background: The mainstay of treatment for early-stage follicular lymphoma is local radiotherapy, with a possible role for anti-CD20 monoclonal antibody (mAb). We aimed to evaluate the effect of these treatments...
2.
DAgostino M, Rota-Scalabrini D, Belotti A, Bertamini L, Arigoni M, De Sabbata G, et al.
Blood Cancer J
. 2024 Jun;
14(1):94.
PMID: 38849344
Additional copies of chromosome 1 long arm (1q) are frequently found in multiple myeloma (MM) and predict high-risk disease. Available data suggest a different outcome and biology of patients with...
3.
Guerra L, Chauvie S, Fallanca F, Bergesio F, Marcheselli L, Durmo R, et al.
Eur J Nucl Med Mol Imaging
. 2024 May;
51(11):3311-3321.
PMID: 38795120
Purpose: To evaluate the reliability of the Deauville score (DS) in therapy response assessment and to define the prognostic value of the metabolic response of end of induction (EOI) [F]FDG...
4.
Mauro F, Scalzulli P, Scarfo L, Minoia C, Murru R, Sportoletti P, et al.
Cancers (Basel)
. 2024 Mar;
16(6).
PMID: 38539561
Real-world data in clinical practice are needed to confirm the efficacy and safety that ibrutinib has demonstrated in clinical trials of patients with chronic lymphocytic leukemia (CLL). We described the...
5.
Iannitto E, Ferrero S, Bommier C, Drandi D, Ferrante M, Bouabdallah K, et al.
Haematologica
. 2024 Mar;
109(7):2297-2302.
PMID: 38497158
No abstract available.
6.
Stathis A, Pirosa M, Orsucci L, Feugier P, Tani M, Ghesquieres H, et al.
Haematologica
. 2024 Feb;
109(8):2564-2573.
PMID: 38385243
The IELSG38 trial was conducted to investigate the effects of subcutaneous (SC) rituximab on the complete remission (CR) rate and the benefits of SC rituximab maintenance in patients with extranodal...
7.
Conconi A, Chiappella A, Ferreri A, Stathis A, Botto B, Sassone M, et al.
Blood Adv
. 2024 Jan;
8(6):1541-1549.
PMID: 38181782
Primary testicular diffuse large B-cell lymphoma (PTL) is characterized by high risk of contralateral testis and central nervous system (CNS) relapse. Chemoimmunotherapy with intrathecal (IT) CNS prophylaxis and contralateral testis...
8.
Duell J, Abrisqueta P, Andre M, Gaidano G, Gonzales-Barca E, Jurczak W, et al.
Haematologica
. 2023 Aug;
109(2):553-566.
PMID: 37646664
Tafasitamab, an anti-CD19 immunotherapy, is used with lenalidomide for patients with autologous stem cell transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma based on the results of the phase II L-MIND study...
9.
Gini G, Tani M, Tucci A, Marcheselli L, Cesaretti M, Bellei M, et al.
Blood
. 2023 Jul;
142(17):1438-1447.
PMID: 37418685
Treatment of diffuse large B-cell lymphoma (DLBCL) in older patients is challenging, especially for those who are not eligible for anthracycline-containing regimens. Fondazione Italiana Linfomi (FIL) started the FIL_ReRi study,...
10.
Oliva E, Riva M, Niscola P, Santini V, Breccia M, Giai V, et al.
J Clin Oncol
. 2023 Jun;
41(28):4486-4496.
PMID: 37294914
Purpose: In myelodysplastic syndromes (MDS), severe thrombocytopenia is associated with poor prognosis. This multicenter trial presents the second-part long-term efficacy and safety results of eltrombopag in patients with low-risk MDS...